Study of a new PET tracer for kidney cancer imaging
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a new imaging agent called 18F-NY104 to see if it can help doctors see kidney cancer tumors on a PET/CT scan. If you have known or suspected kidney cancer that has spread or come back, this study may help find out if the tracer works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have kidney cancer that is suspected or confirmed, or it has come back or spread after treatment.
- You have at least one measurable tumor that can be seen on a scan.
- You are fully active or able to carry out light activities (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You agree to use effective birth control during the study and for 6 months after (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that might help doctors see whether a kidney mass is cancer before surgery. It may help guide treatment decisions.
This trial uses a special PET scan to detect if kidney cancer remains or returns after treatment. It may help find cancer that's hard to see on other scans.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This study tests a new type of PET scan that uses a tracer called 68Ga-RCCB6 to see kidney cancer more clearly. It compares this scan to another PET scan (68Ga-PSMA) to help doctors stage the cancer, check treatment response, and detect any return of the disease.
This study tests a new kind of PET scan that might better detect kidney cancer. It involves an injection of a special imaging agent and a scan to see if the cancer shows up clearly.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.